Nasdaq · CIK 0001061983 · PHARMACEUTICAL PREPARATIONS
CYTOKINETICS, INCORPORATED
CYTK chart by TradingView
PRICE HISTORY
LIVE · NASDAQCYTK chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.1B
- EBITDA
- $-0.6B
- FREE CASH FLOW
- $-0.5B
- EPS
- $-6535.68
- GROSS MARGIN
- —
- ROIC
- 158.71%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
-99%31.9x5921.4x
⤢
P / SALES (TTM)
0.2x
-97%0.0x32.8x
⤢
P / BOOK
—
-99%0.0x5.6x
⤢
EV / EBITDA (TTM)
—
-83%25.1x149.7x
⤢
EV / REVENUE (TTM)
0.5x
-90%-25.5x25.8x
⤢
FCF YIELD (TTM)
-5160.81%
-5147.8pp-15653.38%6.74%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.0B
-52%⤢
EBITDA (DERIVED)
$-0.2B
-614%⤢
NET INCOME
$-0.2B
-696%⤢
EPS (DILUTED)
$-1504.79
-195030%⤢
REVENUE GROWTH YOY
-57.13%
-700.3pp-52194.44%26714.86%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-573.55%
-552.5pp-40653.82%138061.11%
⤢
RETURN ON CAPITAL
583.56%
+583.5pp-2395.88%5249.87%
⤢
RETURN ON EQUITY (TTM)
—
-502.4pp-3124.97%17.44%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN-625.95%
NET MARGIN-694.39%
FCF MARGIN-573.55%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.2B
$0.2B⤢
STOCK-BASED COMP
$0.0B
+1814%⤢
CAPITAL EXPENDITURE
$0.0B
+1316%⤢
SHARES OUTSTANDING
0.00B
-100%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.3B
+742%⤢
TOTAL DEBT
$0.3B
+827%⤢
DEBT / EBITDA (TTM)
—
-68%1.5x11.2x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 120.90%INSIDERS 0.65%OTHER / RETAIL 0.00%632 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14.08% | 17.5M | $1.35B | -1.1% |
| Blackrock Inc. | 13.30% | 16.5M | $1.27B | +0.9% |
| FMR, LLC | 8.62% | 10.7M | $823.1M | -16.3% |
| Wellington Management Group, LLP | 6.44% | 8.0M | $614.8M | +0.9% |
| Vanguard Portfolio Management LLC | 4.70% | 5.8M | $448.6M | NEW |
| State Street Corporation | 4.62% | 5.7M | $441.0M | -1.4% |
| Vanguard Capital Management LLC | 4.41% | 5.5M | $421.3M | NEW |
| Avoro Capital Advisors LLC | 2.68% | 3.3M | $255.9M | NEW |
| Geode Capital Management, LLC | 2.58% | 3.2M | $246.8M | +5.2% |
| Bank of America Corporation | 2.51% | 3.1M | $239.9M | +6.3% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.